Related references
Note: Only part of the references are listed.
Article
Gerontology
Divya Bhagianadh et al.
Summary: Despite high enthusiasm for the COVID-19 vaccine, some older adults remain hesitant, influenced by their information sources. This study found that older adults who relied on healthcare providers, social media, and other sources were more likely to express negative intent towards the vaccine.
JOURNAL OF APPLIED GERONTOLOGY
(2022)
Article
Medicine, General & Internal
George N. Ioannou et al.
Summary: The study aims to determine the effectiveness of COVID-19 vaccines in the healthcare system of the U.S. Department of Veterans Affairs. Research on over 2 million individuals who received the Moderna or Pfizer-BioNTech COVID19 vaccines showed a vaccine effectiveness of 69% against SARS-CoV-2 infection and 86% against SARS-CoV-2-related death.
ANNALS OF INTERNAL MEDICINE
(2022)
Review
Infectious Diseases
Charan Thej Reddy Vegivinti et al.
Summary: This study reviewed current evidence from randomized clinical trials on the efficacy of antivirals for COVID-19 treatment. It found that antivirals were more effective when administered early in the disease course, but none demonstrated efficacy in reducing COVID-19 mortality. Larger randomized controlled trials are needed to establish efficacy conclusively.
BMC INFECTIOUS DISEASES
(2022)
Article
Virology
Rabia Bag Soytas et al.
Summary: The study compared the antibody levels of patients aged 60 and older who received different COVID-19 vaccine regimens, showing that the immunity formed after two doses of CoronaVac plus one dose of Pfizer-BioNTech was significantly higher in older adults than after three doses of CoronaVac.
JOURNAL OF MEDICAL VIROLOGY
(2022)
Article
Medicine, General & Internal
Sue Ann Costa Clemens et al.
Summary: A study was conducted to evaluate the safety and immunogenicity of a third dose of heterologous or homologous vaccines in Brazilian adults who had previously received two doses of CoronaVac. The results showed that a third dose of heterologous vaccines (recombinant adenoviral vectored vaccine or mRNA vaccine) significantly increased immune responses and could improve protection against infection.
Article
Infectious Diseases
Saranya Sridhar et al.
Summary: This study evaluated the safety and immunogenicity of a SARS-CoV-2 vaccine with different adjuvants and dosing schedules. The results showed that two doses of the vaccine induced robust immune responses in both SARS-CoV-2 naive and non-naive adults, with acceptable safety and reactogenicity. These findings support the progression to phase 3 evaluation of the vaccine.
LANCET INFECTIOUS DISEASES
(2022)
Article
Medicine, General & Internal
J. Sadoff et al.
Summary: The Ad26.COV2.S vaccine was found to be 52.9% effective against moderate to severe-critical Covid-19 after a single dose, with protection lasting for at least 6 months. Efficacy varied depending on the Covid-19 variant, but higher protection was observed against severe cases, medical intervention, and death compared to other outcomes.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Cell Biology
Simone Lanini et al.
Summary: Safe and effective COVID-19 vaccines are crucial for ending the pandemic. A vaccine called GRAd-COV2, based on a gorilla adenovirus and expressing the spike protein of SARS-CoV-2, has been evaluated for safety and immunogenicity in healthy younger and older adults.
SCIENCE TRANSLATIONAL MEDICINE
(2022)
Article
Biotechnology & Applied Microbiology
Hui Ouyang et al.
Summary: This study aimed to understand the prevalence and determinants of COVID-19 vaccine hesitancy in mainland China. Lack of confidence and risk were identified as factors of COVID-19 vaccine hesitancy, while age, occupation status, and income levels were significantly associated with vaccine hesitancy. Furthermore, the frequency and diversity of social media use, media trust, and health information literacy were found to be significantly correlated with COVID-19 vaccine hesitancy.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2022)
Article
Immunology
Yue Zhang et al.
Summary: A new functional furin site, which plays a key role in promoting SARS-CoV-2 infection, has been discovered. This site is also present in related viruses found in bats and pangolins.
EMERGING MICROBES & INFECTIONS
(2022)
Review
Immunology
Anselm Jorda et al.
Summary: The efficacy of convalescent plasma treatment for Covid-19 remains uncertain. A systematic review and meta-analysis of randomized controlled trials found that treatment with convalescent plasma did not result in lower all-cause mortality or improved disease progression in patients with Covid-19, regardless of disease severity and baseline antibody status.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Pharmacology & Pharmacy
Maria Jose et al.
Summary: This study aims to estimate the incidence and predictors of adverse events following COVID-19 vaccination in India. The results show that most adverse reactions are minor and younger age, history of allergy, and comorbidities, particularly asthma, are major predictors for the development of adverse events.
CURRENT DRUG SAFETY
(2022)
Article
Cell Biology
Xiao-Chun Song et al.
Article
Immunology
Fengcai Zhu et al.
Summary: The Ad5-vectored COVID-19 vaccine with a single dose was safe and well-tolerated in children and adolescents aged 6-17 years, and it induced robust immune responses. However, the boosting effect of the homologous prime-boost regime given 56 days apart was found to be limited.
CLINICAL INFECTIOUS DISEASES
(2022)
Article
Immunology
Xuan Ying Poh et al.
Summary: This study found that heterologous mRNA-1273 booster vaccination induced a stronger neutralizing response against the Omicron variant in older individuals compared to homologous BNT123b2 vaccination.
CLINICAL INFECTIOUS DISEASES
(2022)
Article
Geriatrics & Gerontology
Elizabeth M. Goldberg et al.
Summary: This study reveals the differences in COVID-19 presentations among older adults, who are more likely to have atypical symptoms. However, the atypical presentations of COVID-19 in older adults visiting the emergency department are not associated with a higher risk of mechanical ventilation and/or death. These findings highlight the importance of widespread COVID-19 testing among older adults in the emergency department to facilitate accurate diagnosis and timely treatment.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
(2022)
Article
Biotechnology & Applied Microbiology
Nasamon Wanlapakorn et al.
Summary: This study assessed the reactogenicity and immunogenicity of heterologous regimens for COVID-19 vaccines in healthy Thai adults. The adverse events were mild and well tolerated overall. Heterologous regimens showed higher antibody responses and neutralizing activities. Spike-specific IgA response was detected only in the heterologous group. The interferon gamma response was detected in both heterologous groups after two-dose vaccination.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2022)
Review
Biotechnology & Applied Microbiology
Elham Jamshidi et al.
Summary: The duration of immunity following COVID-19 vaccination is still unknown. This systematic review provides insights into the persistence of different antibodies for available vaccines. Both BNT162b2 and mRNA-1273 vaccines induce the production of IgA antibodies, which may help prevent asymptomatic transmission. Antibodies from mRNA-1273 vaccine were detectable for up to 6 months, followed by AZD1222 for 3 months, and Ad26.COV2.S and BNT162b2 vaccines for 2 months. The BNT162b2 vaccine generates anti-spike IgGs 11 days after the first dose, peaking at day 21, while AZD1222 shows a neutralizing effect 22 days after the first dose. These vaccines also induce T-cell mediated immune responses, with AZD1222, Ad26.COV2.S, and mRNA-1273 vaccines inducing T-cell immunity at days 14-22, 15, and 43 after the first dose, respectively. For BNT162b1 and BNT162b2 vaccines, T-cell immunity is induced 7 days and 12 weeks after the booster dose, respectively.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2022)
Review
Oncology
Yiming Shao et al.
Summary: The rapid identification and sharing of the SARS-CoV-2 genomic sequence by Chinese scientists has greatly contributed to the development of COVID-19 diagnostics, drugs, and vaccines. However, the challenges posed by virus variants and waning vaccine immunity are significant. Vaccination strategies need to be adapted to maintain population immunity, and further research is necessary to develop more effective vaccines and understand optimal vaccination strategies.
FRONTIERS OF MEDICINE
(2022)
Article
Geriatrics & Gerontology
Maxence Meyer et al.
Summary: The study aimed to assess the dynamics of SARS-CoV-2 anti-RBD-IgG response in older individuals after COVID-19 infection or vaccination. It was found that vaccination after infection can maintain significantly higher antibody titer levels for a prolonged period of time.
Article
Immunology
Jesus San Roman et al.
Summary: This study analyzed the immune response of residents and staff in nursing homes after receiving the COVID-19 vaccine. The study found that younger age and prior COVID-19 infection were associated with stronger humoral immune response after vaccination. However, the immune response may wane over time and reinfection seems to be more frequent in older adults.
Article
Gerontology
Boaz M. Ben-David et al.
Summary: This study examined the factors influencing compliance to the booster COVID-19 vaccine among older adults in Israel. The findings showed that a sense of control and lower vaccination hesitancy were associated with earlier vaccination and rejection of the vaccine. Increased trust was only related to the difference between early vaccinations and vaccine rejection.
JOURNAL OF APPLIED GERONTOLOGY
(2022)
Review
Virology
Rashed Noor
Summary: The world is nearing the end/recovery stage of the COVID-19 pandemic and understanding the host immune responses and protection mechanisms is crucial for the development of vaccines and monitoring their effectiveness.
Article
Immunology
Jerald Sadoff et al.
Summary: Single-dose Ad26.COV2.S elicits durable antibody responses and immune memory. Boosting increases binding and neutralizing antibody levels rapidly and robustly, even with a quarter vaccine dose, and is more effective with a longer interval since primary vaccination.
Article
Microbiology
Barbara M. Schultz et al.
Summary: This study reports the impact of a booster dose of CoronaVac on the immune response against Delta and Omicron variants. Four weeks after the booster dose, there was a significant increase in neutralizing antibodies, and specific T cells reached their peak. Furthermore, the immune response induced by the booster showed activity against Delta and Omicron variants.
Article
Immunology
Rapisa Nantanee et al.
Summary: This study evaluated the immunogenicity of a half-dose BNT162b2 booster after AZD1222 and found that the lower dose vaccine provided comparable immune responses to the standard dose.
Article
Immunology
Yuntao Zhang et al.
Summary: This study evaluated the immunogenicity and safety of the COVID-19 vaccine in individuals aged >= 60 years with hypertension or(/and) diabetes. The vaccine showed good immunogenicity with a seroconversion rate of 100% and non-inferior post-vaccination geometric mean titers compared to the healthy population. The rates of vaccine-related adverse reactions were low and no serious adverse events were reported. The vaccine was well-tolerated and effective in this population.
Article
Immunology
Xavier Saez-Llorens et al.
Summary: This study evaluated the immunogenicity and safety of the COVID-19 vaccine candidate CVnCoV in younger and older adults. The results showed that two doses of 12 µg of CVnCoV were well tolerated and induced robust immune responses in both age groups.
Review
Immunology
Purvita Chowdhury et al.
Summary: This review aims to evaluate the potential impact of the SARS-CoV-2 virus on the COVID-19 management system, including aspects such as immune responses, clinical presentations, and the pathophysiology of available vaccines and their adverse events.
Article
Health Care Sciences & Services
Enagnon Kazali Alidjinou et al.
Summary: This study evaluated the persistent immunogenicity offered by a third dose of BNT162b2 against Delta and Omicron variants in nursing home residents. The results showed that the booster dose significantly increased antibody levels and induced neutralizing effects against Delta and Omicron in the majority of participants. Further research is needed to determine if repeated booster doses or new specific vaccines should be considered for protecting these vulnerable patients against Omicron and future SARS-CoV-2 variants.
LANCET REGIONAL HEALTH-EUROPE
(2022)
Article
Health Care Sciences & Services
Malin Spetz et al.
Summary: This study found that among Swedish adults aged 60 years and older as of May 17, 2021, factors such as younger age, male sex, lower income, living alone, and being born outside Sweden were associated with lower Covid-19 vaccination uptake. Intersectional analysis revealed significant differences in vaccination rates within different sociodemographic subgroups.
LANCET REGIONAL HEALTH-EUROPE
(2022)
Article
Geriatrics & Gerontology
Leonardo Arregoces-Castillo et al.
Summary: This study evaluated the effectiveness of COVID-19 vaccines in preventing hospitalization and death in adults aged 60 and older in Colombia. The results showed that all analyzed vaccines were effective in preventing hospitalization and death. This is a promising outcome for the national vaccination program and other countries using these vaccines. Efforts should be made to improve vaccine coverage among older adults, and booster doses should be considered for this age group.
LANCET HEALTHY LONGEVITY
(2022)
Editorial Material
Geriatrics & Gerontology
Miles D. Witham et al.
Editorial Material
Geriatrics & Gerontology
Roy L. Soiza et al.
Summary: The safety and efficacy of COVID-19 vaccines in older people are crucial for their success, but there is currently a lack of data. While some Phase III trials have made efforts to recruit older people, those with co-morbidities and frailty have still been largely excluded. Older people, their carers, and healthcare professionals will need to make decisions on vaccination acceptance based on limited evidence.
Review
Cell Biology
Yiyin Chen et al.
Summary: The COVID-19 pandemic originating from Wuhan in December 2019 has had far-reaching health and socioeconomic impacts worldwide. The disease caused by SARS-CoV-2 is highly heterogeneous, with age, gender, and comorbidities playing key roles in disease severity and outcomes. Aging and dysregulation of immune function are thought to contribute to the increased vulnerability of older adults to severe COVID-19. Further research on immune responses to SARS-CoV-2 infection, particularly in different age groups, is crucial for understanding disease heterogeneity and developing effective vaccines.
AGEING RESEARCH REVIEWS
(2021)
Article
Medicine, General & Internal
J. Sadoff et al.
Summary: The study conducted a multicenter, placebo-controlled, phase 1-2a trial, with participants randomly assigned to receive the Ad26.COV2.S vaccine. The results showed that the safety and immunogenicity profiles of the vaccine support further development.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Immunology
Luigi Cari et al.
Summary: The study found that the frequency of severe adverse events in ChAdOx1 nCoV-19 and Ad26.COV2.S vaccine recipients is significantly higher compared to BNT162b2 COVID-19 vaccine recipients, suggesting potential risks associated with virus-based vaccines. However, the frequency of SAE types varies among recipients in different age groups.
JOURNAL OF AUTOIMMUNITY
(2021)
Article
Medicine, General & Internal
Raches Ella et al.
Summary: The study reported the clinical efficacy of the BBV152 vaccine against COVID-19 infection in Indian adults. The vaccine demonstrated high efficacy in preventing laboratory-confirmed symptomatic COVID-19 and was well tolerated with no safety concerns raised in this interim analysis.
Article
Medicine, General & Internal
Ann R. Falsey et al.
Summary: The clinical trial in the United States, Chile, and Peru showed that the AZD1222 vaccine was both safe and effective in preventing symptomatic and severe Covid-19 cases, with an overall estimated efficacy of 74% and a higher efficacy of 83.5% in participants 65 years of age or older. The high vaccine efficacy was consistent across various demographic subgroups, and antibodies increased significantly after each dose.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Peter Richmond et al.
Summary: A study in Australia evaluated the dose-finding and adjuvant justification of the SCB-2019 vaccine against SARS-CoV-2. The vaccine, which contains a stabilised trimeric form of the spike protein (S-Trimer) combined with AS03 or CpG/Alum adjuvants, elicited robust humoral and cellular immune responses in both younger and older adults.
Article
Infectious Diseases
Zhiwei Wu et al.
Summary: The study showed that CoronaVac vaccine is safe and well tolerated in older adults, and is able to induce neutralizing antibody levels. The highest dose of 3 μg of the vaccine can generate neutralizing antibody levels similar to the 6 μg dose, supporting the use of the 3 μg dose CoronaVac in phase 3 trials.
LANCET INFECTIOUS DISEASES
(2021)
Article
Multidisciplinary Sciences
Cuiyan Wang et al.
Summary: This study compared the mental health status during the COVID-19 pandemic in the general population of seven middle income countries in Asia, revealing significant differences among these countries. Risk factors for adverse mental health included younger age, higher education background, single or separated status, discrimination by other countries, and contact with people with COVID-19. On the other hand, protective factors for mental health included male gender, living with children or more people in the same household, employment, confidence in doctors, high perceived likelihood of survival, and spending less time on health information.
Article
Medicine, General & Internal
Neil Formica et al.
Summary: This study confirmed the high immunogenicity and good tolerability of the 2-dose regimen of 5-mu g NVX-CoV2373 in younger adults. Additionally, in older adults, the 2-dose regimen of 5 mu g was also well tolerated and showed sufficient immunogenicity to support its use in late-phase efficacy studies.
Article
Immunology
Jiaqi Zhang et al.
Summary: A study showed that 90.7% of vaccinated individuals had NAb seroconversion, with all participants who seroconverted after the first dose being females with relatively high prevaccine estradiol levels. Individuals without seroconversion tended to have lower lymphocyte counts and higher serum SAA levels. Additionally, young vaccine recipients had significantly higher peak NAb titers compared to elderly recipients.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2021)
Review
Microbiology
Shea A. Lowery et al.
Summary: Severe disease from COVID-19 is characterized by significant immunopathology driven by unbalanced innate immune response with limited and delayed interferon response, leading to excessive proinflammatory cytokine production and cellular infiltrates in the respiratory tract causing lung pathology. Effective therapeutics for severe COVID-19 patients depend on understanding the pathological elements of this dysregulated innate immune response, as well as identifying therapeutic strategies targeting these elements of the innate response.
CELL HOST & MICROBE
(2021)
Article
Medicine, General & Internal
Eric J. Haas et al.
Summary: This study assessed the real-world effectiveness of the Pfizer-BioNTech mRNA COVID-19 vaccine BNT162b2 in Israel, showing high efficacy in preventing SARS-CoV-2 infections, hospitalizations, severe disease, and death. As vaccine coverage increased, there were marked declines in SARS-CoV-2 outcomes, indicating that COVID-19 vaccination can help control the pandemic.
Article
Biochemistry & Molecular Biology
Jingxin Li et al.
Summary: The messenger RNA vaccine candidate BNT162b1, encoding the receptor-binding domain of the SARS-CoV-2 spike protein, showed safety and high levels of humoral and T cell responses in an Asian population, including younger and older Chinese adults. Local reactions and systemic events post-vaccination were generally dose-dependent, transient, and mild to moderate.
Article
Medicine, General & Internal
Ya-Jun Shu et al.
Summary: This study evaluated the immunogenicity and safety of the V-01 vaccine, showing that it induced robust immune responses in the two-dose regimen and demonstrated high safety levels. The older adult group exhibited a more favorable safety profile compared to the younger adult group.
CHINESE MEDICAL JOURNAL
(2021)
Article
Infectious Diseases
Baltazar Nunes et al.
Summary: The study found that mRNA vaccines significantly reduced the risk of COVID-19-related hospitalizations and deaths in older adults, with a VE of 94% against hospitalizations and 96% against mortality. The protection did not wane 98 days after the second dose of the vaccine.
Editorial Material
Infectious Diseases
Bipin Adhikari et al.
LANCET INFECTIOUS DISEASES
(2021)
Article
Medicine, General & Internal
S. J. Thomas et al.
Summary: BNT162b2 vaccine remains highly effective and safe over the course of 6 months post-vaccination, with efficacy rates ranging from 86% to 100% across different demographics and risk factors for Covid-19. The vaccine also shows a high efficacy against severe disease, with particularly promising results observed in South Africa against the B.1.351 variant.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Youn Young Choi et al.
Summary: The study examined the safety of the COVID-19 vaccine for adults aged 75 and older who received two doses at a vaccination center in South Korea. The frequency of acute adverse reactions within 15-30 minutes after injection was 8.5 cases per 1,000 doses, with most reactions not requiring special treatment.
JOURNAL OF KOREAN MEDICAL SCIENCE
(2021)
Article
Medicine, General & Internal
Kunsulu Zakarya et al.
Summary: The QazCovid-in (R) vaccine, developed in Kazakhstan, showed good safety and tolerability in phase 1 and 2 clinical trials, inducing significant immune response that lasts at least 6 months.
Article
Medicine, General & Internal
Wanshen Guo et al.
Summary: The study assessed the safety and immunogenicity of an inactivated COVID-19 vaccine in Chinese adults, showing it to be well tolerated and immunogenic in both younger and older adults. Different dosing schedules were evaluated and could be further assessed for long-term safety and efficacy in phase 3 trials.
Article
Immunology
Manish Sadarangani et al.
Summary: Most COVID-19 vaccines aim to induce immune responses, particularly neutralizing antibodies (NAbs), against the spike protein of the virus. mRNA vaccines have shown efficacy after just one dose, while adenovirus vaccines elicit polyfunctional antibodies and strong T cell responses. These findings suggest that protection may not solely rely on NAbs but also involve other immune effector mechanisms.
NATURE REVIEWS IMMUNOLOGY
(2021)
Article
Geriatrics & Gerontology
Clara Bonanad et al.
JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION
(2020)
Article
Medicine, General & Internal
L. A. Jackson et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2020)
Article
Multidisciplinary Sciences
J. -F. Daoust
Article
Medicine, General & Internal
Edward E. Walsh et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2020)
Article
Medicine, General & Internal
E. J. Anderson et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2020)
Article
Medicine, General & Internal
Maheshi N. Ramasamy et al.
Article
Biotechnology & Applied Microbiology
Kuldeep Dhama et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2020)
Article
Geriatrics & Gerontology
Aman Nanda et al.
AGING CLINICAL AND EXPERIMENTAL RESEARCH
(2020)
Review
Biotechnology & Applied Microbiology
Janet M. Lord
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2013)
Editorial Material
Medicine, General & Internal
Gordon H. Guyatt et al.
BRITISH MEDICAL JOURNAL
(2008)
